Search research articles
Contact Us
Filters
Showing results (51-60 of 97) with videos related to
Page
of 10
Sort By:
Journal of the American College of Cardiology
|
October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Michael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
Diabetes, Obesity & Metabolism
|
September 14, 2016
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
Dirk J Blom, Michael J Koren, Eli Roth, et al.
Clinical Cardiology
|
June 21, 2012
Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy
Payal Kohli, Nihar R Desai, Robert P Giugliano, et al.
JAMA Cardiology
|
December 13, 2018
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data
Arman Qamar, Robert P Giugliano, Anthony C Keech, et al.
JAMA
|
May 15, 2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, et al.
Clinical Cardiology
|
February 1, 2014
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy
Jennifer G Robinson, William J Rogers, Bettina S Nedergaard, et al.
Circulation
|
November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
Michael J Koren, Robert P Giugliano, Frederick J Raal, et al.
Circulation
|
January 16, 2008
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia
Jalal K Ghali, Inder S Anand, William T Abraham, et al.
Circulation
|
July 26, 2013
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial
Nihar R Desai, Payal Kohli, Robert P Giugliano, et al.
Journal of the American College of Cardiology
|
April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
Erik Stroes, David Colquhoun, David Sullivan, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 97) with videos related to
Sort By:
Page
of 10
Journal of the American College of Cardiology
|
October 26, 2019
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Michael J Koren, Marc S Sabatine, Robert P Giugliano, et al.
Diabetes, Obesity & Metabolism
|
September 14, 2016
Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
Dirk J Blom, Michael J Koren, Eli Roth, et al.
Clinical Cardiology
|
June 21, 2012
Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy
Payal Kohli, Nihar R Desai, Robert P Giugliano, et al.
JAMA Cardiology
|
December 13, 2018
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data
Arman Qamar, Robert P Giugliano, Anthony C Keech, et al.
JAMA
|
May 15, 2014
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, et al.
Clinical Cardiology
|
February 1, 2014
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy
Jennifer G Robinson, William J Rogers, Bettina S Nedergaard, et al.
Circulation
|
November 21, 2013
Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial
Michael J Koren, Robert P Giugliano, Frederick J Raal, et al.
Circulation
|
January 16, 2008
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia
Jalal K Ghali, Inder S Anand, William T Abraham, et al.
Circulation
|
July 26, 2013
AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial
Nihar R Desai, Payal Kohli, Robert P Giugliano, et al.
Journal of the American College of Cardiology
|
April 4, 2014
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
Erik Stroes, David Colquhoun, David Sullivan, et al.
Page
of 10